[View Original Text] 

Korean company AIDOT Inc. (CEO Jung Jae-hoon) has announced that its patent application for the Cerviray AI-related technology has been successfully registered as a "Deep 

Learning System" patent in China.

This "Deep Learning System" patent pertains to the general configuration and operation of the Cerviray artificial intelligence system. With the patent now registered in China, AIDOT 

can protect the technology behind its AI solutions, which it has developed and implemented. 

The patent specifically covers the process of an artificial intelligence software system that operates through learning modules, tuning modules, transmission modules, storage 

modules, and diagnostic modules. It is characterized by its ability to display real-time analysis information and update learning data.

This patent holds significant importance as it broadly protects the unique features of AI-assisted software for analyzing and diagnosing abnormalities in cervical cancer screening.

AIDOT's CEO, Jae-hoon Jeong, stated that although conducting business in China has been challenging in recent years, the registration of this patent provides a basis for protecting 

AIDOT's intellectual property. Consequently, the risks associated with entering the Chinese market have been reduced. He further mentioned that due to the increasing inquiries 

regarding the adoption of Cerviray from Chinese partners, AIDOT is considering re-entering the Chinese market.

AIDOT is actively pursuing opportunities in the Chinese market by promoting the Cerviray system at the Obstetrics and Gynecology Conference held in Shanghai from July 15th to 

16th. They plan to resume full-scale business activities in China by resolving the licensing issues within the country.

AIDOT has been recognized for its technological expertise and has been selected for various government projects since its establishment. They have introduced several AI-based 

systems, including the Cerviray AI system for cervical cancer detection, the real-time endoscopy AI solution GIGA dot AI for gastrointestinal diseases, COLON dot AI, and the 

BIO dot AI system for diagnosing alcoholic liver disease using microbiome data. These products have demonstrated AIDOT's independent technology and capabilities. Currently, the 

Cerviray AI system has been successfully commercialized, and AIDOT is developing other products in preparation for their commercial launch.

Korean economy TV / 14th. Jul. 2023. / Reporter Joon-sik Park